Reducing Cardiovascular Risk With Effective Management Of LDL Cholesterol - A Round Table Discussion
Published: 18 December 2020
-
Views:
79 -
Likes:
7
-
Views:
79 -
Likes:
7
-
2m 24sPart 1 Chapter 1: Welcome and introductions Kausik (Kosh) Ray, Lale Tokgözoğlu, Christie Ballantyne
-
14m 23sPart 3 Chapter 3: Current approaches to controlling LDL-C – what do the guidelines say? Christie Ballantyne
-
15m 53sPart 4 Chapter 4: Challenges in achieving guideline-based LDL-C targets in the real world Kausik (Kosh) Ray
Overview
This round table is designed to provide clinicians with a better understanding of the long-term CV risks of LDL-C exposure. In addition to reviewing the pathogenesis of atherosclerosis and assessing the long term implications of elevated LDL-C, this meeting will consider current guidance around controlling LDL-C, the challenges in achieving LDL-C targets, and evaluate how emerging strategies are contributing to LDL-C management.
Each chapter will comprise of a short presentation by the named medical expert followed by a panel discussion amongst all faculty.
Learning objectives
- Outline the pathogenic nature and clinical risk of extended exposure to elevated LDL-C
- Describe the clinical challenges in achieving guideline-based LDL-C goals
- Compare and contrast LDL-C lowering therapies
More from this programme
Part 1
Chapter 1: Welcome and introductions
Part 2
Chapter 2: The role of long-term exposure to elevated LDL-C in the pathogenesis of atherosclerosis and clinical risk
Part 3
Chapter 3: Current approaches to controlling LDL-C – what do the guidelines say?
Part 4
Chapter 4: Challenges in achieving guideline-based LDL-C targets in the real world
Part 5
Chapter 5: Contemporary approaches to managing LDL-C and cardiovascular risk
Part 6
Chapter 6: Summary
1 session | |
Chapter 6: Summary | Watch now |
Faculty Biographies
Kausik (Kosh) Ray
Professor of Public Health
Kausik Ray is currently Professor of Public Health, Deputy Director of Imperial Clinical Trials Unit and Head of Commercial Trials within the Department of Public Health and Primary Care, School of Public Health, Imperial College London, Consultant Cardiologist and Chief Clinical Officer and Head of Trials – Discover Now as well as NIHR ARC National Lead of Cardiovascular Disease.
Professor Ray received his medical education (MB ChB, 1991) at the University of Birmingham Medical School, his MD (2004) at the University of Sheffield, a postdoctoral fellowship at Harvard Medical School and finally an MPhil in epidemiology (2007) from the University of Cambridge.
A Fellow of the American College of Cardiology, the European Society of Cardiology, the American Heart Association and the Royal College of Physicians, Kausik Ray is also a member of the British Cardiovascular Society and President-Elect of the European Atherosclerosis Society, also serving on the EAS Consensus…
Lale Tokgözoğlu
Professor Cardiology, Haceteppe University, Ankara, Turkey
S. Lale Tokgözoglu is Professor of Cardiology at Hacettepe University, Ankara, Turkey. She is currently the President of the European Atherosclerosis Society and Deputy Editor of the European Heart Journal. She chaired the ‘Atherosclerosis and Vascular Biology Working Group of the European Society of Cardiology’ between 2008 and 2010. Professor Tokgözoglu has served on the Board of the Turkish Society of Cardiology and was elected to be the first female President of the Society in its history, between 2014-2016. During that time, she worked with the Ministry of Health to develop ‘Heart Health policies’ and strategies. She also chaired the Dyslipidaemia Working Group of the Turkish Society of Cardiology.
Professor Tokgözoglu has contributed to several Guidelines and Consensus Papers on dyslipidaemia and Preventive Cardiology both in Europe and nationally. She was a member of the Steering Committee of the EUROASPIRE studies and has also served on the Board of the Prevention…
Christie Ballantyne
Chief of Cardiology and Chief of Cardiovascular Research at Baylor College of Medicine, Houston, Texas
Christie Ballantyne is an internationally-renowned expert on lipids, atherosclerosis and heart disease prevention. His research interest in the prevention of heart disease has led him to become an established investigator for the American Heart Association and to receive continuous funding from the NIH since joining the faculty in 1988 in basic research of leukocyte- endothelial interactions, translational research in biomarkers and clinical trials.
Over the past 32 years, his many accomplishments have included being elected as Fellow of the American Association for the Advancement of Science, the American Society of Clinical Investigation, and the Association of American Physicians. In 2012 he received the American College of Cardiology Distinguished Scientist Award (Basic Domain). In 2014 and 2015, Thomson Reuters recognized Christie as one of “The World's Most Influential Scientific Minds.” Clarivate Analytics, Web of Science, named Dr. Ballantyne as a “Highly Cited…